New Data Demonstrates Strong Support For Surgalign's SImmetry Sacroiliac Joint Fusion System

Surgalign Holdings Inc SRGA announced the publication of results from EVoluSIon (EVSI) study of clinical outcomes following minimally invasive sacroiliac joint (SIJ) fusion with decortication.

• The EVoluSIon Clinical Study reports 12-month clinical outcomes following minimally invasive SIJ fusion using the SImmetry Sacroiliac Joint Fusion system to treat SIJ dysfunction. 
• The study included 250 patients.
• The results demonstrated statistically significant improvements in both pain and disability and a statistically significant reduction in the number of patients using opioids.
• Also See: Surgalign Shares Tank After $20 Equity Capital Raise.
• Specifically, 72.2% of patients achieved a reduction in pain, 62.5% of patients achieved a reduction in disability.
• 57.1% of patients reported (N=201) cessation of opioid use, and 68.7% achieved radiographic fusion. 
• The SIJ has been reported to be the source of pain in approximately 18-30% of patients presenting with chronic low back pain and increases to more than 40% in patients with prior lumbar fusion.
• Price Action: SRGA shares are up 1.09% at $0.34 during the market session on the last check Thursday.